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Mongrel or beagle dogs were submitted to bile duct 
ligation. or to extraenteric biliary diversion by means 
of choledochoureter08tomy. The kinetics of intrave-
nously administered FK508 was not changed from con-
trol status two weeks after bile duct ligation. but the 
bioavailability of orally administered FK508 was nearly 
quadrupled. Following oral administration. the absorp-
tion of FK508 was highly variable. The results indicate 
that in dogs FK508 is absorbed from the intestine just 
as efficiently in the absence of enteric bile and in pres-
ence of exogenous bile salt supplement when compared 
with its absorption in presence of normal bile drainage. 
These findings with FK508 are different from those 
with cyclosporine after biliary obstruction or diversion 
and will have important practical as well as experimen-
tal ramifications. 
The immunosuppressive agent, FK506. (1) is a macrocyclic 
lactone that is highly lipid soluble. This drug is an effective 
1 This work was supported by Research Grants from the Veterans 
Administration and by Project Grant DK 29961 from the National 
Institutes of Health, Bethesda, Maryland. 
, Addreaa correspondence to: Thomas E. Starzl. M.D .• Ph.D., 3601 
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immunosuppressant in rats, dogs, monkeys, baboons. and hu-
mans after liver, kidney, or heart transplantation (2). FK506 is 
largely metabolized by the liver prior to elimination from the 
body (3) and the status of the liver is expected to influence its 
elimination. Since liver dysfunction or bile duct ligation de-
creases the availability of bile salts for solubilization of lipid 
soluble drugs, normal biliary drainage was predicted to be an 
important condition for the optimal absorption of FK506, as is 
the case with absorption of oral cyclosporine (4). In the present 
study, this expectation could not be supported in dogs submit-
ted to bile duct ligation or extraenteric biliary diversion. 
MATERIALS AND METHODS 
Bile duct ligatIOn. Five female mongrel dogs weighing between 18 
and 22 kg and six female beagle dogs weighing between 8 and 10 kg 
were maintained in a 12-hr light-dark cycle from 7 A.M. to 7 P.M. On 
the day of the study the dogs were fasted overnight and for 4 hr after 
drug administration. Water wu allowed ad libitum. Intravenous FK506 
wu diluted in normal saline and administered III a bolus (0.2 mg/kg) 
over 15 secs. Blood I8mpies were obtained immediately before and 5, 
10, 15,30, 45 min after the bolus. Later, samples were obtained at 1. 2. 
3, 4. 6, 8, 12. 18. 24. and 30 hr. Three days after the i.v. study. oral 
FK506 (1 mg/kg) wu administered in a hard gelatin capsule. Blood 
.......-
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samples were drawn before treatment. 15. 30. and 45 min afterward. 
and later at 1. 2. 3, 4, 6.8, 12, 16, 24. and 30 hr. 
Five days later. the common bile and cystic ducts were doubly ligated 
and divided under general anesthesia with pentobarbital-halothane 
anesthesia. The animals were given 1 g/day intramuscular cefamandole 
for three days postoperatively. Then 14 days later. the FK506 kinetic 
studies were performed in the same way as described preoperatively. 
Biliary diversion with choledochoureterostomy. Female beagle dogs 
(n-6) weighing approximately 10 kg and with the conditions described 
above were given an oral dose of 1 mg/kg FK506 and blood samples 
were obtained at 0, 0.25, 0.5, 0.75. 1. 2, 3. 4, 6, 8. 12, 16. and 24 hr. 
Three days later, the dogs received 1 mg/kg of FK506 orally, 15 min 
after 1 g of lecithin and 250 mg of chenodeoxycholic acid. and FK506 
kinetics was studied as described earlier. Nine days later, choledoch-
oureterostomy was performed after right nephrectomy, using a previ-
ously described technique (5). Intramuscular cefamandole was used as 
in the previous section. Two weeks after biliary diversion, the oral 
FK506 absorption study was repeated, first with out any exogenous 
bile supplement and three days later, after administration of 250 mg 
chenodeoxycholic acid and 1 g lecithin. 
Blood samples were centrifuged at room temperature and the plasma 
was frozen at -70·C until analyzed for FK506. The FK506 concentra-
tion was measured in plasma by Tamura's enzyme immunoassay 
method (6). This assay has a coefficient of variation of 22% at 0.5 ngl 
ml and 10% at 2.1 ng/m!. Liver function tests were carried out at the 
outset, and at the time of the subsequent studies. 
The plasma concentration time curve was analyzed by standard 
techniques (7). Statistical Analysis was carried out using a nonpara-
metric test (Mann Whitney's U test). t test, or ANOV A as appropriate, 
with P<0.05 being statistically significant. 
RESULTS 
Bile duct ligation. Serum GOT, GPT, alkaline phosphatase, 
and total bilirubin were in the normal range before bile duct 
ligation and were elevated in all of the dogs after bile duct 
ligation (Table O. While serum creatinine was lower after 
surgery, the BUN was normal throughout. Table 2 describes 
the biochemical parameters in dogs before and after biliary 
diversion. While the serum GOT and GPT were normal after 
biliary diversion, alkaline phosphatase and total bilirubin were 
slightly elevated after surgery, indicating minimal changes in 
the hepatic function. 
The plasma concentration-versus-time curve following in-
travenous administration of FK506 to a mongrel dog (No.6) 
before and after bile duct ligation is shown in Figure 1. The 
kinetics of FK506 in dogs can be adequately described by a 
two-compartment model, with a rapid initial distribution phase 
followed by a slower disposition phase. The pharmacokinetic 
TABLE 1. Biochemical parameters in dogs before and after bile duct 
ligation (n = III 
Preoperative Postoperative P value 
SGOT (lUlU 33±U" 357±251 <0.05 
SGPT (1U/LI 33±7 2707±1556 <0.05 
Alkaline phosphatase 61±36 6549±3061 <0.05 
(lUlL) 
Total bilirubin (mg%) 0.2±0.1 5.7±2.6 <0.05 
Serum creatinine 1.l±0.3 0.8±0.2 <0.05 
(mg%) 
BUN 13±3 1l±4 NSb 
Total proteins (g%) 5.5±O.6 6.2±0.5 <0.05 
Albumin (g%) 3.7±O.4 3.6±O.4 NS 
"Mean ±SD. 
'(NS) not significant.. 
TABLE 2. Biochemical parameters in dogs before and after biliary 
diversion (n = 6) 
Preoperative 14·day Pvalue Postoperative 
SGOT (lUlL) 36±10" 44±27 NSb 
SGPT (lUlL) 36±18 144±174 NS 
Alkaline phosphate 36±3 415±155 <0.05 
(IU/L) 
Total bilirubin (mg%) 0.1±0.1 0.3±0.2 <0.05 
Serum Creatinine 1.l±0.1 1.2±0.2 NS 
(mg%) 
BUN 13±4 23±6 <0.05 
Total proteins (g%) 6.2±0.3 5.9±0.7 NS 
Albumin (g%) 4.0±0.3 3.4±0.4 <0.05 
"Mean ± SD. 
b (NS) not significant. 
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FIGURE 1. Plasma concentration-versus-time curve following an 
intravenous dosing (0.2 mg/kg) in mongrel dog No.6 before (e) and 
after (.) bile duct ligation. 
parameters calculated after i.v. FK506 are shown in Tables 3 
and 4 for mongrel and beagle dogs, before and after bile duct 
ligation. Bile duct ligation did not significantly alter the dis-
position rate constant, half life, or the plasma clearance of 
FK506 in this group of dogs. However, the volume of distribu-
tion of FK506 was significantly increased in the mongrel dogs 
after bile duct ligation (P<O.05). 
The plasma concentration-versus-time curve following oral 
administration of FK506 to dog No.3 before and after bile duct 
ligation is shown in Figure 2. The pharmacokinetic parameters 
calculated in five mongrel and six beagle dogs after oral admin-
istration are listed in Tables 5 and 6. These results indicate a 
rapid absorption of FK506, with a mean peak plasma concen-
tration of 2.8 (+ 1.1) and 7.8 (+2.0) ng/ml being reached in 1.2-
1.3 hr. After bile duct ligation, the disposition rate constant, 
half-life, and the time to reach peak plasma concentrations 
were significantly altered while peak plasma concentrations 
were not different. More importantly, there was a significant 
increase in the area under the plasma concentration-versus-
time curve (AUC). Consequently, the oral bioavailability of 
FK506 in bile duct ligated animals was significantly higher (3-
4-fold) than that observed in normal animals. 
Choledochoureterostomy. Two weeks after this operation, all 
6 of the dogs had near-normal liver function teats. They were 
all eating and healthy. Biliary diversion or addition of exoge-
nOlla bile salta did not reault in any significant chanpa in the 
peak plaama concentrations, half·life, or the AUC after oral 
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TABLE 3. FK506 pharmacokinetics ii.v.) in mongrel dogs before and 
after bile duct ligation 
Dog No. 
1 
3 
4 
5 
6 
Mean 
SD 
Disposition rate 
constant (hr-1 ) 
Pre. Post. 
0.0757 0.0677 
0.0527 0.0475 
:--iDa 0.0943 
0.0769 0.1112 
0.0720 0.0688 
0.0693 0.0779 
±0.0098 ±0.0223 
a (NO) not determined. 
Half·life (hr) 
Pre. Post. 
9.2 10.2 
13.2 14.6 
ND 7.4 
9.0 6.2 
9.6 10.1 
10.3 9.7 
±1.7 ±2.9 
Clearance 
(ml/min) 
Pre. Post. 
2239 2699 
1943 1665 
ND ND 
3125 4072 
1992 3750 
2325 3047 
±475 ±945 
Volume of 
distribution 
at steady 
state 
Pre. Post. 
1385 2240 
1972 1928 
~a 2384 
1446 2040 
1801 2040 
1651 2324 
±282 ±3SSa 
'Significantly different from the control values (p<0.05). 
TABLE 4. FK506 kinetics (i.v.) in beagle dogs before and after bile 
duct ligation 
Disposition rate con· Half·life (hr) Clearance 
Dog No. stant (hr- 1) (ml/min) 
Pre. Post. Pre. Post. Pre. Post. 
1 0.1115 0.0550 6.2 13.5 315 251 
2 0.1165 0.0530 6.0 13.1 366 313 
3 0.1312 O.OSSO 5.3 8.1 296 347 
4 0.0400 0.0644 17.3 10.8 253 400 
6 0.0858 0.0586 8.1 11.8 368 249 
Mean 0.10 0.06 8.6 11.5 320 312 
SD ::0.04 ±0.01 ±5.0 ±2.2 ::49 ±65 
P NS NS NS 
F< KINEtICS PC OCSE 
DEFf~ 
t 
FIGURE 2. Plasma concentration versus-time-{:urve following oral 
administration (I mg/kg) in mongrel dog No.6 before (., and after 1.' bile duct ligation. 
FK506 administration. The time to reach peak plasma concen· 
tration was. however. increased significantly after biliary diver-
sion (Table il. 
DISCUSSION 
The pharmacokinetics of intravenous FK506 were altered 
very little by bile duct ligation. This is different from the effect 
of bile duct ligation on cyclosporine. which has a reduced 
elimination under these circumstances (8). The difference be-
tween the 2 drugs given intravenously requires explanation 
since both agents are very lipid-soluble and are eliminated 
TABLE 5. Oral FK506 kinetics in mongrel dogs before and after bile 
duct ligation 
Disposition rate 
Dog No. constant (hr-1) 
Pre. Post. 
1 0.096 0.042 
3 0.120 0.096 
4 0.123 0.066 
5 0.088 0.087 
6 0.114 0.084 
Half·life 
Ihr) 
Pre. Post. 
7.2 16.5 
5.8 7.2 
5.6 lOA 
7.9 8.0 
6.1 8.2 
Maximum T' . h plasma Ime to reac 
concentra. m81lmum 
tion (n / plasma con· 
mil g centratlOn (hr) 
Pre. Post. Pre. Post. 
1.9 4.0 2 4 
2.3 11.3 2 
2.8 3.2 4 
4.9 1.8 1 3 
2.5 3.1 2 6 
Bioavail· 
ability 
(%) 
Pre. Post. 
9 56 
9 42 
21 
12 23 
5 60 
Mean 0.114 0.075" 6.5 10.1" 2.9 4.7 1.4 3.8" 9 40" 
SO ±0.002 ±0.021 0.9 3.8 ±1.2 ±3.8 ±0.55 ±1.55 ±3 ±16 
"Significantly different from Pre. values (P<0.05). 
TABLE 6. Oral FK506 kinetics in beagle dogs before and after bile 
duct ligation 
Dog No. 
1 
2 
3 
4 
5 
6 
Disposition rate 
constant (hr-') 
Pre. Post. 
0.0778 0.0962 
0.1135 0.104 
0.0498 0.118 
0.0794 0.1166 
Half·life 
(hr) 
Pre. Post. 
8.9 7.2 
6.1 6.7 
13.9 5.9 
8.7 5.9 
0.0562 0.1210 12.3 5.8 
0.0691 0.0983 10.0 7.1 
Maximum 
plasma 
concentra· 
tion (ng/ 
mn 
Pre. POlt. 
10.2 29.2 
4.0 8.8 
4.2 8.7 
9.2 B.3 
8.6 8.8 
10.6 14.6 
Time to 
reach maxi· Bioavail· 
mum plasma ability (%) 
concentra· 
tion (hr) 
Pre. Post. Pre. Post. 
2 2 8.8 33.3 
0.75 2 3.6 17.8 
2 3 4.7 19.1 
0.75 1 6.1 13.3 
1.0 4 - 20.5 
0.5 2 9.2 26.1 
Mean 0.07 
SO ±0.02 
0.11" 10.0 604" 7.8 13.1 1.2 2.3" 6.5 21.7" 
±0.01 2.8 0.6 ±2.0 ±8.3 ±O.07 ±l.0 ±2.5 ±7.0 
"Significantly different from Pre. values (P<0.05). 
TABLE 7. Effect of biliary diversion and bile salt supplementation on 
FK506 oral absorption 
Peak concen· Time to (AUC) Half·life tratlOn (ng/ peak (hr) (mg/ml/hr) (hr) 
mll 
Control 10.9±7.5 1.l±0.9 44A±38.1 8.9±l.7 
Control and bile salt 11.9±10.9 0.9±0.2 36A±25.9 8.7±2.1 
Biliary diversion 5.4±3.1 2.3±1.0" 33.3±20.0 9.8±1.8 
Biliary diversion and i.2±3.5 2.2±1.o" 38.6±26.2 9.7±1.5 
bile salt 
a Significantly different from the control animals (P<0.05). 
primarily by hepatic metabolism (3. 4). However. cyclosporine 
is cleared slowly from the body and thus is classified a8 a "low-
clearance" drug, whereas FK506 has a plasma clearance that is 
actually higher than the hepatic blood flow. 
The 2·week period of bile duct ligation probably caused 
minimal impairment of the hepatic blood flow in these dogs in 
spite of the significant but moderate hepatic injury that was 
measurable by standard liver function tests. Since FK506 ap-
pears to be a high-clearance drug and its elimination after i.v. 
administration depends on hepatic blood flow. severe liver 
dysfunction leading to reduced hepatic blood flow would be 
expected eventually to be a factor that would decreue the 
elimination of intravenously administered FK506. Apparently, 
p ------------
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this had not yet occurred within 14 days of duct ligation in 
both mongrel and beagle dogs. 
In contrast to the minimum changes in intravenous phar-
macokinetics, the oral pharmacokinetics of FK506 were drast-
ically altered by bile duct ligation. The time to reach peak 
plasma FK506 concentrations and the bioavailability were sig-
nificantly increased. Again, this was an unexpected finding 
since the bioavailability of orally administered cyciosporine is 
greatly reduced after bile duct ligation (8). It is possible that 
presystemic metabolism of FK506 is impaired in animals after 
bile duct ligation resulting in increased oral bioavailability. It 
was not possible to explain these paradoxical results completely 
without further experimentation in additional dogs who had 
pure biliary diversion, which was done with choledochoureter-
ostomy. This procedure eliminated the potential artifact of 
liver injury caused by duct ligation; hepatic function tests were 
minimally altered, and the livers were histopathologically nor-
mal at 2 weeks. Biliary diversion by itself did not significantly 
alter the extent of absorption of FKS06. The increased time to 
reach peak FK506 plasma concentrations following biliary di-
version presumably indicates a decreased rate of absorption of 
FKS06. Addition of bile salts in the presence or in the absence 
of endogenous bile did not alter the extent of FK506 absorption. 
Taking the biliary obstruction and diversion experiments 
together, the results indicate that absorption of FKS06, in 
contrast to that of cyciosporine, which is bile salt-dependent 
(8-10), is actually not significantly altered by the absence of 
bile. The differential effect of bile on FKS06 and cyciosporine 
absorption can be rationalized as follows. The dose of FKS06 
(about 0.15 mg/kg) is nearly one-flftieth of that of cyclosporine 
(about 7.S mg/kg). The fluid volume in the gut is sufficient to 
dissolve FK506 from the solid dispersion formulation and bile 
contributes minimally to FK 506 dissolution. On the other 
hand, bile is necessary for solubilizing the administered dose of 
cyclosporine and lack of bile results in decreased cyciosporine 
absorption. 
Much further work will be required before the full explana-
tion for this unexpected finding can be delineated. However, it 
is clear at a practical level that the assumption that past 
practices with cyciosporine will be applicable to oral FKS06 
administration are unwarranted. When the draining T tube of 
a patient on oral cyciosporine is ciamped, it is necessary to 
reduce the dosage in order to prevent augmented absorption 
and consequent large increases in cyciosporine blood levels 
(11). It has already been noted in similar patientS treated with 
FKS06 that downward adjustments in FKS06 dosages are not 
required (12, 13). 
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